Author:
Palmer D H,Hussain S A,Smith A J,Hargreaves S,Ma Y T,Hull D,Johnson P J,Ross P J
Publisher
Springer Science and Business Media LLC
Reference6 articles.
1. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2009) ; 10 (1): 25–34.
2. El-Serag HB, Mason AC . Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) ; 340 (10): 745–750.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) ; 359 (4): 378–390.
4. National Institute for Health and Clinical Excellence Final Appraisal Determination. Sorafenib for the treatment of advanced hepatocellular carcinoma
http://www.nice.org.uk/nicemedia/live/12019/46312/46312.pdf
.
5. Palmer DH, Johnson PJ (2006) Prognostic factors in hepatocellular carcinoma. In: UICC Prognostic Factors in Cancer 3rd edn John Wiley & Sons: Hoboken, NJ, USA.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献